PLI develops and markets eukaryotic proteins for pharmaceutical, biotech and drug discovery companies with the aim of speeding up drug discovery and drug design. This includes stable isotopically labeled proteins.

PLI provides a proprietary technology to produce labelled membrane proteins and metabolic precursors for protein labelling

PLI provides services on development and marketing of various biological compounds.
This includes stable isotope labelling.